WO2002028853A1 - Compose de benzylamine, son procede de production et produit intermediaire correspondant - Google Patents
Compose de benzylamine, son procede de production et produit intermediaire correspondant Download PDFInfo
- Publication number
- WO2002028853A1 WO2002028853A1 PCT/JP2001/008616 JP0108616W WO0228853A1 WO 2002028853 A1 WO2002028853 A1 WO 2002028853A1 JP 0108616 W JP0108616 W JP 0108616W WO 0228853 A1 WO0228853 A1 WO 0228853A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- producing
- benzylamine compound
- same
- halogeno
- intermediate therefor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pyridine Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001292320A AU2001292320A1 (en) | 2000-10-02 | 2001-10-01 | Benzylamine compound, process for producing the same, and intermediate therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000301563 | 2000-10-02 | ||
JP2000-301563 | 2000-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002028853A1 true WO2002028853A1 (fr) | 2002-04-11 |
Family
ID=18783085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/008616 WO2002028853A1 (fr) | 2000-10-02 | 2001-10-01 | Compose de benzylamine, son procede de production et produit intermediaire correspondant |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001292320A1 (ja) |
WO (1) | WO2002028853A1 (ja) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004030695A1 (en) * | 2002-10-04 | 2004-04-15 | The University Of Reading | Treatment of vascular diseases |
WO2005016862A1 (en) * | 2003-08-14 | 2005-02-24 | Asahi Kasei Pharma Corporation | Substituted arylalkanoic acid derivative and use thereof |
WO2005034869A3 (en) * | 2003-10-08 | 2005-07-07 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2008090117A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
US7645764B2 (en) | 2006-11-09 | 2010-01-12 | Roche Palo Alto Llc | Kinase inhibitors and methods for using the same |
US7678792B2 (en) | 2006-10-20 | 2010-03-16 | Irm Llc | Compositions and methods for modulating c-kit and PDGFR receptors |
US8158828B2 (en) | 2005-11-28 | 2012-04-17 | Gtx, Inc. | Nuclear receptor binding agents |
JP2012533541A (ja) * | 2009-07-15 | 2012-12-27 | インテリカイン, エルエルシー | 特定の化学物質、組成物および方法 |
US8546451B2 (en) | 2005-11-28 | 2013-10-01 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
AU2011265521B2 (en) * | 2005-07-15 | 2013-10-31 | Merck Serono Sa | JNK inhibitors for the treatment of endometreosis |
US8637706B2 (en) | 2005-11-28 | 2014-01-28 | Gtx, Inc. | Nuclear receptor binding agents |
US9290497B2 (en) | 2011-01-10 | 2016-03-22 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US9409856B2 (en) | 2005-11-28 | 2016-08-09 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US9427418B2 (en) | 2009-02-23 | 2016-08-30 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US9527847B2 (en) | 2012-06-25 | 2016-12-27 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US9624161B2 (en) | 2009-02-23 | 2017-04-18 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US9822131B2 (en) | 2008-01-04 | 2017-11-21 | Intellikine Llc | Certain chemical entities, compositions and methods |
US11110096B2 (en) | 2014-04-16 | 2021-09-07 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991009844A1 (en) * | 1990-01-04 | 1991-07-11 | Pfizer Inc. | Substance p antagonists |
WO1992017449A1 (en) * | 1991-03-26 | 1992-10-15 | Pfizer Inc. | Stereoselective preparation of substituted piperidines |
WO1994004496A1 (en) * | 1992-08-19 | 1994-03-03 | Pfizer Inc. | Substituted benzylamino nitrogen containing non-aromatic heterocycles |
WO1994013663A1 (en) * | 1992-12-10 | 1994-06-23 | Pfizer Inc. | Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists |
WO1995008549A1 (en) * | 1993-09-22 | 1995-03-30 | Glaxo Group Limited | 3-(5-tetrazolyl-benzyl)amino-piperidine derivatives and antagonists of tachykinins |
WO1997001554A1 (en) * | 1995-06-28 | 1997-01-16 | Merck Sharp & Dohme Limited | Piperidine and morpholine derivatives and their use as therapeutic agents |
WO1997021702A1 (en) * | 1995-12-11 | 1997-06-19 | Merck Sharp & Dohme Limited | 3-benzylaminopyrrolidines and -piperidines as tachykinin receptor antagonists |
-
2001
- 2001-10-01 WO PCT/JP2001/008616 patent/WO2002028853A1/ja active Application Filing
- 2001-10-01 AU AU2001292320A patent/AU2001292320A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991009844A1 (en) * | 1990-01-04 | 1991-07-11 | Pfizer Inc. | Substance p antagonists |
WO1992017449A1 (en) * | 1991-03-26 | 1992-10-15 | Pfizer Inc. | Stereoselective preparation of substituted piperidines |
WO1994004496A1 (en) * | 1992-08-19 | 1994-03-03 | Pfizer Inc. | Substituted benzylamino nitrogen containing non-aromatic heterocycles |
WO1994013663A1 (en) * | 1992-12-10 | 1994-06-23 | Pfizer Inc. | Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists |
WO1995008549A1 (en) * | 1993-09-22 | 1995-03-30 | Glaxo Group Limited | 3-(5-tetrazolyl-benzyl)amino-piperidine derivatives and antagonists of tachykinins |
WO1997001554A1 (en) * | 1995-06-28 | 1997-01-16 | Merck Sharp & Dohme Limited | Piperidine and morpholine derivatives and their use as therapeutic agents |
WO1997021702A1 (en) * | 1995-12-11 | 1997-06-19 | Merck Sharp & Dohme Limited | 3-benzylaminopyrrolidines and -piperidines as tachykinin receptor antagonists |
Non-Patent Citations (3)
Title |
---|
CARBONNELLE A.C. ET AL., TETRAHEDRON LETT., vol. 39, no. 25, 1998, pages 4467 - 4470, XP002912910 * |
CHEMICAL ABSTRACTS, vol. 51, Columbus, Ohio, US; abstract no. 8081F-8082C, XP002906375 * |
SCI. PROC. ROY. DUBLIN SOC., vol. 27, 1956, pages 111 - 117 * |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004030695A1 (en) * | 2002-10-04 | 2004-04-15 | The University Of Reading | Treatment of vascular diseases |
US7470807B2 (en) | 2003-08-14 | 2008-12-30 | Asahi Kasei Pharma Corporation | Substituted arylalkanoic acid derivatives and use thereof |
JP2007528362A (ja) * | 2003-08-14 | 2007-10-11 | 旭化成ファーマ株式会社 | 置換アリールアルカン酸誘導体及びその用途 |
WO2005016862A1 (en) * | 2003-08-14 | 2005-02-24 | Asahi Kasei Pharma Corporation | Substituted arylalkanoic acid derivative and use thereof |
US7449582B2 (en) | 2003-10-08 | 2008-11-11 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
JP2007508310A (ja) * | 2003-10-08 | 2007-04-05 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
WO2005034869A3 (en) * | 2003-10-08 | 2005-07-07 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
AU2004279427B2 (en) * | 2003-10-08 | 2008-07-03 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
JP4758349B2 (ja) * | 2003-10-08 | 2011-08-24 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
AU2011265521B2 (en) * | 2005-07-15 | 2013-10-31 | Merck Serono Sa | JNK inhibitors for the treatment of endometreosis |
US9409856B2 (en) | 2005-11-28 | 2016-08-09 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US8637706B2 (en) | 2005-11-28 | 2014-01-28 | Gtx, Inc. | Nuclear receptor binding agents |
US8158828B2 (en) | 2005-11-28 | 2012-04-17 | Gtx, Inc. | Nuclear receptor binding agents |
US9051267B2 (en) | 2005-11-28 | 2015-06-09 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US8546451B2 (en) | 2005-11-28 | 2013-10-01 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US7678792B2 (en) | 2006-10-20 | 2010-03-16 | Irm Llc | Compositions and methods for modulating c-kit and PDGFR receptors |
US8106068B2 (en) | 2006-10-20 | 2012-01-31 | Irm Llc | Compositions and methods for modulating c-kit and PDGFR receptors |
US7645764B2 (en) | 2006-11-09 | 2010-01-12 | Roche Palo Alto Llc | Kinase inhibitors and methods for using the same |
WO2008090117A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
US9655892B2 (en) | 2008-01-04 | 2017-05-23 | Intellikine Llc | Certain chemical entities, compositions and methods |
US11433065B2 (en) | 2008-01-04 | 2022-09-06 | Intellikine Llc | Certain chemical entities, compositions and methods |
US9216982B2 (en) | 2008-01-04 | 2015-12-22 | Intellikine Llc | Certain chemical entities, compositions and methods |
US9822131B2 (en) | 2008-01-04 | 2017-11-21 | Intellikine Llc | Certain chemical entities, compositions and methods |
US9624161B2 (en) | 2009-02-23 | 2017-04-18 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US9427418B2 (en) | 2009-02-23 | 2016-08-30 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US9522146B2 (en) | 2009-07-15 | 2016-12-20 | Intellikine Llc | Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof |
US9206182B2 (en) | 2009-07-15 | 2015-12-08 | Intellikine Llc | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof |
JP2012533541A (ja) * | 2009-07-15 | 2012-12-27 | インテリカイン, エルエルシー | 特定の化学物質、組成物および方法 |
US9840505B2 (en) | 2011-01-10 | 2017-12-12 | Infinity Pharmaceuticals, Inc. | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof |
USRE46621E1 (en) | 2011-01-10 | 2017-12-05 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US9290497B2 (en) | 2011-01-10 | 2016-03-22 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US10550122B2 (en) | 2011-01-10 | 2020-02-04 | Infinity Pharmaceuticals, Inc. | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof |
US11312718B2 (en) | 2011-01-10 | 2022-04-26 | Infinity Pharmaceuticals, Inc. | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
US9527847B2 (en) | 2012-06-25 | 2016-12-27 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US11110096B2 (en) | 2014-04-16 | 2021-09-07 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US11944631B2 (en) | 2014-04-16 | 2024-04-02 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
Also Published As
Publication number | Publication date |
---|---|
AU2001292320A1 (en) | 2002-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002028853A1 (fr) | Compose de benzylamine, son procede de production et produit intermediaire correspondant | |
WO2002024650A3 (en) | Pyridinone and pyridinethione derivatives having hiv inhibiting properties | |
AU3053999A (en) | Nitrogenous heterocyclic compounds | |
WO2005105096A3 (en) | Fused heterocyclic compounds | |
WO2002044153A8 (en) | 4-6-diphenyl pyridine derivatives as antiinflammatory agents | |
AP2001002205A0 (en) | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase. | |
WO2003064429A1 (fr) | Thienopyrimidines, procedes de fabrication et d'utilisation correspondants | |
EP1640366A4 (en) | HETEROCYCLES METHYLSULFON DERIVATIVE | |
BG104447A (en) | Biphenylamidine derivatives | |
EP1043312A4 (en) | HETEROCYCLIC COMPOUNDS HAVING NOS-INHIBITING ACTIVITIES | |
CA2273303A1 (en) | Thienylsulfonylamino(thio)carbonyl compounds | |
AU9025601A (en) | Cephem compounds and esbl-detecting reagents containing the same | |
HUT75649A (en) | Optically active imidazolidinone derivative and pharmaceutical compositions containing them | |
EP1043311A4 (en) | BIPHENYLAMIDINE DERIVATIVES | |
DK1338596T3 (da) | Fremgangsmåde til fremstilling af antibakterielt middel af carbapenemtypen | |
EP1099690A4 (en) | MONOCYCLIC BETA LACTAM COMPOUNDS AND CHYMASE INHIBITORS THAT CONTAIN THEM | |
TW200740757A (en) | Carboxamide compound and use of the same | |
YU64699A (sh) | Kvaternarna jedinjenja amonijuma kao tahikininski antagonisti | |
WO2001010861A3 (de) | Substituierte heterocyclyl-2h-chromene | |
EP1211253A4 (en) | DIHYDROBENZOFURAN TRICYCLIC DERIVATIVES, THEIR PREPARATION METHOD AND AGENTS | |
WO2007007903A3 (en) | Carboxamide compound and use of the same | |
DE60130916D1 (de) | Neue beta-lactamverbindungen und verfahren zu deren herstellung | |
AU3648093A (en) | Pyrrolidine derivatives useful as 5-HT3-antagonists | |
WO2003004464A3 (de) | Heterozyklische amidderivate und deren verwendung als schädlingsbekämpfungsmittel | |
WO2000043375A3 (de) | Substituierte arylheterocyclen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS KR LC LK LR LT LV MA MG MK MN MX NO NZ PH PL RO SG SI SK TT UA US UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |